Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00160732
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-08
First Post:
2005-09-08
Brief Title:
Allogenic Islet Cell Transplantation
Sponsor:
University of Chicago
Organization:
University of Chicago
Study Overview
Official Title:
Allogenic Islet Cells Human U of Chicago Administered Via Intraportal Infusion and Immunosuppressive Therapy
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety of transplanting human islet cells for controlling hyperglycemia in brittle andor complex patients with type 1 diabetes In addition initial observations will be made with regards to the effectiveness of reversing hypoglycemia with this treatment The Edmonton Protocol of using specific anti-rejection drugs without steroids is also being evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| BB-IND 11228 | None | None | None |